Imigran Neo

Sumatriptan, the active ingredient in Imigran Neo, is a Triptan presented as an oral tablet for oral use. It treats acute migraine attacks in adults, providing rapid relief of headache pain and associated symptoms. GNH USA supplies Imigran Neo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sumatriptan belongs to the triptan class and is used for acute migraine management.

Migraine: Provides rapid relief of migraine headache pain and associated nausea or photophobia when taken at the onset of an attack. Cluster headache: Relieves acute cluster headache episodes by reducing vascular dilation and pain. Acute migraine with aura: Alleviates headache and visual aura symptoms during an acute migraine episode.

Common Side Effects: - Chest tightness or pressure - Tingling or numbness in fingers or face - Nausea or abdominal discomfort - Dizziness or light‑headedness - Fatigue or drowsiness - Warmth or flushing

Serious or Rare Side Effects: - Coronary vasospasm or myocardial infarction - Serotonin syndrome, especially with serotonergic drugs - Severe hypertension or hypertensive crisis - Allergic reactions such as rash, angioedema, or anaphylaxis - Stroke or transient ischemic attack - Severe arrhythmias

Before using Imigran Neo, consider the following precautions: - Cardiovascular disease: avoid use in patients with coronary artery disease or uncontrolled hypertension. - History of stroke or transient ischemic attack: contraindicated. - Concomitant serotonergic agents: assess risk of serotonin syndrome. - Pregnancy and lactation: consult a healthcare professional before use. - Pediatric use: safety and efficacy not established in children. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Sumatriptan may interact with several medication classes.

Major Interactions (Avoid): - MAO inhibitors: increased risk of serotonin syndrome. - SSRIs, SNRIs, or other serotonergic agents: may precipitate serotonin syndrome. - Ergot alkaloids: additive vasoconstrictive effects can cause severe vascular events.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may reduce the therapeutic response of sumatriptan. - Antihypertensive drugs: additive blood‑pressure lowering effects. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise sumatriptan plasma concentrations.